target/Virus_Protease/2

Cysteine protease inhibitor 2 is a cysteine protease inhibitor. Cysteine protease inhibitor 2 inhibited DCT116 and PC3 cells with GI50 values of 6.5 μM and 4.4 μM, respectively.

Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 values between 40 to 204 nM. It exhibits cytotoxic effects on HepG2, HeLa, MDA-MB-231, and MCF-7 cell lines, with IC50 values of 41, 57, 51, and 59 μM, respectively. Additionally, it induces cell cycle arrest and apoptosis specifically in HepG2 cells.

Protease-Activated Receptor-1 Antagonist 2 is an orally active antagonist of protease-activated receptor-1 (PAR-1), demonstrating significant potency with an IC 50 of 7 nM. It exhibits favorable pharmacokinetic characteristics, making it valuable in cardiovascular disease (CVD) research, including studies on atherosclerosis and restenosis [1].

TAPI-2 is a broad-spectrum inhibitor of MMP (IC50: 20 μM), tumour necrosis factorα-converting enzyme (TACE) and a disintegrin and metalloproteinase (ADAM).

HIV-1, HIV-2 Protease Substrate is a compound serving as the substrate for the proteases of both HIV-1 and HIV-2, featuring four residues that allow for conservative substitutions at the substrate binding sites of these enzymes [1].

Influenza virus-IN-2 (compound 19) has anti-influenza A virus activities that is a potent inhibitor of influenza virus with an CC 50 of 150.85 μM and EC 50 of 2.58 μM. Influenza virus-IN-2 concentration-dependently inhibits the PAN endonuclease with EC 50 of 489.39 nM [1].

Protease-Activated Receptor-1 antagonist 2 is a selective, orally active protease-activated receptor-1 (PAR-1) antagonist (IC50: 7 nM). It has shown good pharmacokinetic properties and can be used for studies related to cardiovascular disease (CVD) such as atherosclerosis and restenosis.

HIV-1 protease-IN-2 is a potent inhibitor of HIV-1 protease (IC50: 2.53 nM). HIV-1 protease-IN-2 exhibits antiviral effects against DRV (Darunavir) sensitive or drug resistant HIV-1 mutants.

Hepatitis Virus C NS3 Protease Inhibitor 2 is a peptide inhibitor derived from a product that targets the NS3 protease of the hepatitis C virus (HCV). Its inhibitory activity against the NS3 protease is characterized by a Ki value of 41 nM.

Herpes Virus Inhibitor 2, a compound known for its effectiveness in disrupting the quaternary structure of herpes virus ribonucleotide reductase, functions as a potent inhibitor of viral replication, thereby halting the progression of the herpes virus [1] [2].

Zika virus-IN-2 (Compd 3) is a Zika virus inhibitor (EC 50= 7.4 μM).

Protease-Activated Receptor-2, amide (SLIGKV-NH2) is an agonist of PAR2 (IC50 : 10.4 M)